Skip to main content
Premium Trial:

Request an Annual Quote

Expression Pathology Gets $6.5M Investment from Abraxis

NEW YORK (GenomeWeb News) – Expression Pathology, a Gaithersburg, Md.-based developer of technology for analyzing protein biomarkers in tissue, has received $6.5 million in financing from biopharmaceutical firm Abraxis BioScience.

Expression Pathology said that the funds would be used to apply its Liquid Tissue proteomics technology to the development of personalized medicine assays for measuring protein biomarkers of drug response and disease prognosis to specific patient treatment decisions.

"We believe the ability of our technology to interrogate archived tissue collections to discover and validate protein biomarkers that relate to disease progression, drug response and toxicity, and to measure those biomarkers accurately in standard tissue from clinical trials and medical care, will translate into a tremendously valuable asset," Casey Eitner, president and CEO of Expression Pathology, said in a statement.

Expression Pathology did not disclose how much of an equity stake Abraxis holds in the firm.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.